EPT Disclosure
August 27 2009 - 5:07AM
UK Regulatory
TIDMCEL
RNS Number : 1017Y
Nomura Code Securities Limited
27 August 2009
DEALINGS BY CONNECTED EXEMPT PRINCIPAL TRADERS
WITHOUT RECOGNISED INTERMEDIARY STATUS, OR WITH RI STATUS
BUT NOT DEALING IN A CLIENT-SERVING CAPACITY
(Rule 38.5(b) of the Takeover Code)
1. KEY INFORMATION
+------------------------------------+------------------------------------------+
| Name of exempt principal trader | Nomura Code Securities Limited |
+------------------------------------+------------------------------------------+
| Company dealt in | Celsis International plc |
+------------------------------------+------------------------------------------+
| Class of relevant security to | Ordinary 5p Shares ISIN- GB00B0CD5F69 |
| which the dealings being disclosed | |
| relate (Note 1) | |
+------------------------------------+------------------------------------------+
| Date of dealing | 26-Aug-2009 |
+------------------------------------+------------------------------------------+
2. INTERESTS, SHORT POSITIONS AND RIGHTS TO SUBSCRIBE
* Interests and short positions (following dealing) in the class of relevant
security
dealt in (Note 2)
+------------------------------------+----------+----------+----------+----------+
| | Long | Short |
+------------------------------------+---------------------+---------------------+
| | Number | (%) | Number) | (%) |
+------------------------------------+----------+----------+----------+----------+
| (1) Relevant securities | 6,440 | 0.03 | 0 | 0.00 |
| | | | | |
+------------------------------------+----------+----------+----------+----------+
| (2) Derivatives (other than | 0 | 0 | 0 | 0 |
| options) | | | | |
| | | | | |
+------------------------------------+----------+----------+----------+----------+
| (3) Options and agreements to | 0 | 0 | 0 | 0 |
| purchase/sell | | | | |
| | | | | |
+------------------------------------+----------+----------+----------+----------+
| Total | 6,440 | 0.03 | 0 | 0.00 |
+------------------------------------+----------+----------+----------+----------+
| | | |
+------------------------------------+----------+----------+----------+----------+
* Interests and short positions in relevant securities of the company, other than
the class
dealt in (Note 2)
+------------------------------------+-----------+----------+----------+----------+
| Class of relevant security: | Long | Short |
| | | |
+------------------------------------+----------------------+---------------------+
| | Number | (%) | Number) | (%) |
+------------------------------------+-----------+----------+----------+----------+
| (1) Relevant securities | 0 | 0 | 0 | 0 |
| | | | | |
+------------------------------------+-----------+----------+----------+----------+
| (2) Derivatives (other than | 0 | 0 | 0 | 0 |
| options) | | | | |
| | | | | |
+------------------------------------+-----------+----------+----------+----------+
| (3) Options and agreements to | 0 | 0 | 0 | 0 |
| purchase/sell | | | | |
| | | | | |
+------------------------------------+-----------+----------+----------+----------+
| Total | 0 | 0 | 0 | 0 |
| | | | | |
+------------------------------------+-----------+----------+----------+----------+
* Rights to subscribe (Note 2)
+------------------------------------+------------------------------------------+
| Class of relevant security: | Details |
| | |
+------------------------------------+------------------------------------------+
| n/a | n/a |
+------------------------------------+------------------------------------------+
3. DEALINGS (Note 3)
(a)Purchases and sales
+--------------------------+-----------------------+------------------+
| Purchase/sale | Number of securities | Price per |
| | | unit (Note 4) |
+--------------------------+-----------------------+------------------+
| Purchase | 6,440 | 231p |
+--------------------------+-----------------------+------------------+
| Total Purchases: | 6,440 | |
+--------------------------+-----------------------+------------------+
| | | |
+--------------------------+-----------------------+------------------+
| Total Sales: | Nil | |
+--------------------------+-----------------------+------------------+
(b)Derivatives transactions (other than options)
+-----------------+--------------------+-----------------------+------------------+
| Product name, | Long/short (Note | Number of | Price per unit |
| e.g. CFD | 5) | securities (Note 6) | (Note 4) |
+-----------------+--------------------+-----------------------+------------------+
| n/a | n/a | n/a | n/a |
| | | | |
+-----------------+--------------------+-----------------------+------------------+
(c) Options transactions in respect of existing securities
(i)Writing, selling, purchasing or varying
+-------------+-------------+-------------+----------+-----------+--------+---------------+
| Product | Writing, | Number of | Exercise | Type, | Expiry | Option |
| name, | selling, | securities | price | e.g. | | money |
| e.g. call | purchasing, | to which | | American, | date | paid/received |
| option | varying | the option | | European | | per unit |
| | etc. | relates | | etc. | | (Note 4) |
| | | (Note 6) | | | | |
+-------------+-------------+-------------+----------+-----------+--------+---------------+
| n/a | n/a | n/a | n/a | n/a | n/a | n/a |
| | | | | | | |
+-------------+-------------+-------------+----------+-----------+--------+---------------+
(ii)Exercising
+--------------------------+-------------------------+---------------------------+
| Product name, e.g. call | Number of securities | Exercise price per unit |
| option | | (Note 4) |
| | | |
+--------------------------+-------------------------+---------------------------+
| n/a | n/a | n/a |
| | | |
+--------------------------+-------------------------+---------------------------+
(d)Other dealings (including new securities) (Note 3)
+--------------------------+-----------------------+-----------------------------+
| Nature of transaction | Details | Price per unit (if |
| (Note 7) | | applicable) (Note 4) |
| | | |
+--------------------------+-----------------------+-----------------------------+
| n/a | n/a | n/a |
| | | |
+--------------------------+-----------------------+-----------------------------+
4. OTHER INFORMATION
Agreements, arrangements or understandings relating to options or derivatives
+----------------------------------------------------------------------------+
| Full details of any agreement, arrangement or understanding between the |
| person disclosing and any other person relating to the voting rights of |
| any relevant securities under any option referred to on this form or |
| relating to the voting rights or future acquisition or disposal of any |
| relevant securities to which any derivative referred to on this form is |
| referenced. If none, this should be stated. |
+----------------------------------------------------------------------------+
| None |
| |
+----------------------------------------------------------------------------+
Is a Supplemental Form 38.5(b) attached? (Note 8)NO
+---------------------------------------------+-------------------------------+
| Date of disclosure | 27-Aug-2009 |
+---------------------------------------------+-------------------------------+
| Contact name | Niall Campbell |
+---------------------------------------------+-------------------------------+
| Telephone number | 020 7776 1226 |
+---------------------------------------------+-------------------------------+
| Name of offeree with which connected | Celsis International plc |
+---------------------------------------------+-------------------------------+
| Nature of connection (Note 9) | Financial Adviser |
+---------------------------------------------+-------------------------------+
Notes
The Notes on Form 38.5(b) can be viewed on the Takeover Panel's website
at www.thetakeoverpanel.org.uk
This information is provided by RNS
The company news service from the London Stock Exchange
END
EMMIIFIATVIDFIA
Celadon Pharmaceuticals (LSE:CEL)
Historical Stock Chart
From Oct 2024 to Nov 2024
Celadon Pharmaceuticals (LSE:CEL)
Historical Stock Chart
From Nov 2023 to Nov 2024
